Disease Progression Humans Prognosis Risk Factors Tumor Suppressor Protein p53/*metabolism Urinary Bladder Neoplasms/*metabolism/*pathology Meta-analysis Non-muscle invasive bladder cancer Progression Stage T1 p53

Carcinoma Transitional Cell Cystectomy Female Humans Treatment Outcome *Urinary Bladder Neoplasms

Humans Odds Ratio Pesticides/*adverse effects Risk Urinary Bladder Neoplasms/*chemically induced/epidemiology bladder cancer epidemiology meta-analysis pesticide exposure

androgen receptor bladder cancer meta-analysis prognosis

Biomarkers Tumor/*blood/*genetics Humans MicroRNAs/*blood/*genetics Neoplasm Invasiveness Reverse Transcriptase Polymerase Chain Reaction Urinary Bladder Neoplasms/*blood/*genetics/pathology

Carcinoma/etiology/pathology Case-Control Studies Chronic Disease Humans Risk Urinary Bladder/pathology Urinary Bladder Neoplasms/*etiology/pathology Urinary Tract/*pathology Urinary Tract Infections/*complications/pathology

Adjuvants Immunologic/*therapeutic use BCG Vaccine/*therapeutic use Humans Mycobacterium bovis Urinary Bladder Neoplasms/*drug therapy/pathology BCG vaccine immunotherapy urinary bladder neoplasms

Combined Modality Therapy Cystectomy/*methods Humans Lymph Node Excision/*methods Urinary Bladder Neoplasms/pathology/*surgery

Critical Pathways Cystectomy/*methods/rehabilitation Humans Length of Stay Postoperative Care/*methods Postoperative Complications/*epidemiology *Standard of Care Urinary Bladder Neoplasms/*surgery Urinary Diversion/*methods/rehabilitation Clinical pathways Collaborative care Cystectomy Enhanced recovery Fast track including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Kaplan-Meier Estimate Neoplasm Grading Neoplasm Metastasis Neoplasm Staging Odds Ratio Prognosis Publication Bias Urinary Bladder Neoplasms/*mortality/*pathology/therapy histological variants squamous differentiation urothelial carcinoma of the bladder including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Adult Aged Aged 80 and over Female *Fluorodeoxyglucose F18 Humans Lymphatic Metastasis Male Middle Aged Neoplasm Staging *Positron Emission Tomography Computed Tomography *Radiopharmaceuticals Reproducibility of Results Retrospective Studies Urinary Bladder Neoplasms/*drug therapy/*pathology Bladder cancer Lymph nodes Positron emission tomography Preoperative staging Urinary bladder neoplasms

Carcinoma Transitional Cell/pathology/*surgery Electrocoagulation/*methods Humans Length of Stay Muscle Smooth/pathology Neoplasm Invasiveness *Neoplasm Recurrence Local Operative Time Prospective Studies Retrospective Studies Urinary Bladder/pathology/*surgery Urinary Bladder Neoplasms/pathology/*surgery

*Cystectomy Humans *Quality of Life Treatment Outcome Urinary Bladder Neoplasms/*surgery *Urinary Diversion *Urinary Reservoirs Continent

BCG Vaccine/*adverse effects/immunology/therapeutic use C-Reactive Protein/analysis Cancer Vaccines/*adverse effects/immunology/therapeutic use Databases Factual Dysuria/etiology Humans Lymphadenopathy/etiology Pneumonia/etiology Skin Ulcer/etiology Tuberculosis Vaccines/*adverse effects/immunology Urinary Bladder Neoplasms/*therapy

Biomarkers Tumor/genetics DNA Methylation Epigenesis Genetic *Gene Expression Regulation Neoplastic Humans Prognosis Retrospective Studies Urinary Bladder Neoplasms/*genetics Chromatin remodeling Methylation Non-coding RNA Progression Recurrence Urothelial carcinoma

Administration Intravesical Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Carcinoma Transitional Cell/mortality/*pathology/*therapy Disease Progression Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Mitomycin/administration & dosage Neoplasm Recurrence Local/*prevention & control Neoplasm Staging Randomized Controlled Trials as Topic Risk Factors Survival Rate Thiotepa/administration & dosage Time Factors Urinary Bladder Neoplasms/mortality/*pathology/*therapy Chemotherapy Meta-analysis Non–muscle-invasive bladder cancer Single instillation Systematic review

biomarker diagnosis meta-analysis microRNA muscle-invasive bladder cancer

Administration Intravesical Antineoplastic Agents/administration & dosage/*therapeutic use BCG Vaccine/administration & dosage/*therapeutic use Humans Treatment Outcome Urinary Bladder Neoplasms/*drug therapy

Administration Intravesical Antineoplastic Agents/*administration & dosage Antineoplastic Combined Chemotherapy Protocols/administration & dosage Carcinoma Transitional Cell/*drug therapy/mortality Cyclophosphamide/administration & dosage Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Melphalan/administration & dosage Network Meta-Analysis Semustine/administration & dosage Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality chemotherapy drug therapy single instillation systematic review urinary bladder neoplasm

Adult Aged Aged 80 and over Biomarkers Tumor/*metabolism Cyclin-Dependent Kinase Inhibitor p16/*metabolism *Down-Regulation Female Gene Expression Regulation Neoplastic Humans Lymphatic Metastasis Male Middle Aged Prognosis Survival Analysis Urinary Bladder Neoplasms/metabolism/mortality/*pathology